Yaya Yayi Amfani da Zinbryta da Mene Ne Matsayi Mai Rarraba?
A watan Mayun 2016, Cibiyar Abinci da Drugta ta Amurka ta amince da maganin cutar gyaran cutar Zinbryta (daclizumab) don magance magungunan sake dawo da MS .
Zinbryta magani ne da aka ba a cikin fata a kowane mako 4. An yi imani da aiki ta hanyar hana shafin yanar gizo a kan interleukin-2 (IL-2) -a kwayoyin a cikin tsarin da ke taimakawa wajen kunna tarin jikin T.
Ta hanyar kulle mai karbi a kan interleukin-2, ba a kunna tantanin ƙwayar T don kai farmaki a cikin ƙwaƙwalwar ƙaƙƙarfan kwakwalwa a cikin kwakwalwarka da na kashin baya ba.
Zinbyta na iya aiki ta hanyar kara yawan kwayoyin halitta a cikin tsarin da ba a rigakafi wanda ake kira kullun halitta, wanda ke kashe ƙwayoyin T wadanda aka kunna don kai farmaki akan sheath na myelin.
Kimiyya Bayan Zinbryta
A cikin babban binciken a cikin New England Journal of Medicine, 1841 mahalarta tare da MSD relapsing-MS da aka ba da gangan ba a samu ko dai wani kashi na Zinbryta (daclizumab) kowane mako hudu ko Avonex (interferon β-1a) mako-mako na kusan shekaru uku.
Sakamakon ya bayyana cewa mahalarta wadanda suka karbi Zinbryta yana da kashi 45 cikin dari na rashin lafiya na MS a kowace shekara fiye da wadanda suka karbi Avonex.
Bugu da ƙari, yawan sababbin cutar MS a kan MRI shine kashi 54 cikin 100 na waɗanda suka karbi daclizumab, idan aka kwatanta da waɗanda aka bi da su tare da Avonex.
A cikin wani binciken a Lancet , kusan 600 masu halartar tare da MSD-remitting-MS aka bazuwar don samun ƙaramin kashi na Zinbryta (150mg), kashi mafi girma na Zinbryta (300mg), ko kuma allurar wuribo.
Mahalarta ko masu bincike sun san abin da aka ba da allurar - an kira wannan bincike ne na makafi guda biyu kuma yana kare sakamakon sakamakon rashin jin dadi. Mahalarta sun karbi injections mako-mako na kimanin shekara guda.
Sakamako ya nuna cewa idan aka kwatanta da placebo, kashi na kasa na Zinbryta (150mg) ya rage yawan karfin MS na kashi 54, kuma kashi mafi girma (300mg) ya ragu da kashi 50 cikin 100 na MS.
Sabili da haka, ƙananan ƙananan kashi ya ba da kyakkyawan sakamako, wanda shine dalilin da ya sa aka yi amfani da ƙananan kashi don rage girman tasiri.
Hanyoyin Kyau na Tsarin Zinbryta
Kamar dukkanin magungunan, Zinbryta yana ɗaukar nauyin illa mai cutarwa, wasu ma yiwuwar barazanar rai. Wadannan an lasafta su a matsayin gargadi na akwatin kuma sun hada da:
- ciwon hanta mai tsanani wanda zai iya zama m
- colon ƙonewa
- fata halayen
- Hakanan ƙwayar lymph ya zama girma
Sauran maganganun miyagun ƙwayoyi sun haɗa da yiwuwar mummunar mummunar cutar, da kuma kara yawan haɗari da cututtuka, ciki har da tunanin suicidal.
Dangane da sakamakon illa na al'ada, waɗanda aka ruwaito a cikin binciken da aka kwatanta da Zinbryta zuwa Avonex sun hada da:
- sanyi bayyanar cututtuka
- ƙwayar cutar na numfashi na sama ko mashako
- eczema, rash, ko wani fata dauki
- mura
- ciwon bakin ciki
- ƙaddamar da ƙwayoyin lymph nodes
Sauran yawan abubuwan da suka faru sun hada da haɗuwa a cikin hanta enzyme da ciki.
Saboda yiwuwar wannan mummunar tasiri, Zinbryta kawai aka ba da shawarar ga mutanen da ke da MS waɗanda basu amsa ga biyu ko fiye da sauran hanyoyin MS ba.
Bugu da ƙari, ana iya rubuta shi ne kawai a karkashin shirin da ake kira Ƙaddarin Bincike da Tsarin Nisa (REMS). Wannan yana nufin cewa mai likitancinku dole ne a ƙulla don bi da ku da Zinbryta.
Manufar wannan shirin shine tabbatar da cewa likitancinku yana kula da ku don yiwuwar cutarwa, kamar duba lokutan hawan jini na jini.
Kalma Daga
Yana da ƙarfafawa lokacin da FDA ta amince da sabon sababbin cututtukan cututtuka na MS, kuma labari mai dadi shine cewa akwai karin cikin bututun mai. Wannan an ce, wannan magani yana iya ko ba zai zama daidai ba a gare ku.
Akwai abubuwa da yawa da za a yi la'akari da lokacin zabar wani farfadowa na MS kamar sauran likitocinku, ko kuna iya zama ciki a nan gaba, da kuma rashin damuwa da rashin lahani da suka shafi shi.
Bugu da ƙari, Zinbryta bazai "mafi kyau" fiye da lafiyar MS na yanzu ba. Akwai kawai nazarin daya kwatanta shi zuwa Avonex. Saboda haka, yayin da Zinbryta ya rage yawan relayes idan aka kwatanta da Avonex, ba zamu iya rarraba wannan ga sauran hanyoyin kwantar da MS ba.
Sources:
Gold R et al. Daclizumab tsarin samar da yawan amfanin ƙasa mai yawa a relapsing-remitting multiple sclerosis (SELECT). Lancet. 2013; 381) 9884): 2167-75.
Kapos L et al. Daclizumab HYP zuwa Interferon Beta-1a Sauko da Multiple Sclerosis. N Engl J Med . 2015; 373 (15): 1418-28.
Milo R. Inganci da amincin daclizumab da tasirinsa a cikin maganin sclerosis da yawa. Tsarancin Mara Neurol. 2014; 7 (1): 7-21.
Abinci da Drug Administration na Amurka da ke Bayyana Bayanan. (2016). Zinbryta.